Metabolite page

Showing information for HMDB0000564 ('PC(16:0)', 'PC(16:0/16:0)', 'palmitoyl-palmitoyl-glycerophosphocholine')

Metabolite information
HMDB ID	HMDB0000564
Synonyms	1,2-Bis[hexadecanoyl]-sn-glycero-3-phosphocholine 1,2-Bis[palmitoyl]-sn-glycero-3-phosphocholine 1,2-Dihexadecanoyl-sn-glycerol-3-phosphorylcholine 1,2-Dipalmitoyl-3-sn-phosphatidylcholine 1,2-Dipalmitoyl-L-3-phosphatidylcholine 1,2-Dipalmitoyl-L-a-lecithin 1,2-Dipalmitoyl-L-a-phosphatidylcholine 1,2-Dipalmitoyl-L-alpha-lecithin 1,2-Dipalmitoyl-L-alpha-phosphatidylcholine 1,2-Dipalmitoyl-L-lecithin 1,2-Dipalmitoyl-L-phosphatidylcholine 1,2-Dipalmitoyl-rac-glycero-3-phosphocholine 1,2-Dipalmitoyl-sn-3-glycerophosphocholine 1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine 1,2-Dipalmitoyl-sn-glycero-3-phosphorylcholine 1,2-Dipalmitoyl-sn-glycerol-3-phosphocholine 1,2-Dipalmitoyl-sn-glycerophosphocholine 1,2-Dipalmitoyl-sn-glycerophosphorylcholine 1,2-Dipalmitoyl-sn-glyceryl-3-phosphocholine 1,2-Dipalmitoyl-sn-phosphatidylcholine 1,2-Dipalmitoylphosphatidylcholine 1,2-L-a-Dipalmitoylphosphatidylcholine 1,2-L-alpha-Dipalmitoylphosphatidylcholine 1,2-dihexadecanoyl-rac-glycero-3-phosphocholine 1,2-dipalmitoylglycero-3-Phosphocholine 1-16:0-2-16:0-Phosphatidylcholine 16:0-16:0-PC Cellular membrane Colfosceril palmitate Colfosceril palmitic acid Colfoscerili palmitas Cytoplasma DPPC Dietary supplement Digestion Dihexadecanoyl-sn-glycero-3-phosphocholine Dipalmitoyl L-a-phosphatidylcholine Dipalmitoyl L-alpha-phosphatidylcholine Dipalmitoyl phosphatidylcholine Dipalmitoyl-GPC Dipalmitoyl-L-3-glycerylphosphorylcholine Dipalmitoyl-L-a-lecithin Dipalmitoyl-L-a-phosphatidylcholine Dipalmitoyl-L-alpha-lecithin Dipalmitoyl-L-alpha-phosphatidylcholine Dipalmitoyl-sn-3-phosphatidylcholine Dipalmitoylphosphatidylcholine Extracellular region Fauna GPC[16:0/16:0] Inner membrane L-1,2-Dipalmitoyl-a-lecithin L-1,2-Dipalmitoyl-alpha-lecithin L-1,2-Dipalmitoylphosphatidylcholine L-DPPC L-Dipalmitoyl lecithin L-a-1,2-Dipalmitoyl lecithin L-a-DPPC L-a-Dipalmitoylecithin L-a-Dipalmitoyllecithin L-a-Dipalmitoylphosphatidylcholine L-alpha-1,2-Dipalmitoyl lecithin L-alpha-DPPC L-alpha-Dipalmitoylecithin L-alpha-Dipalmitoyllecithin L-alpha-Dipalmitoylphosphatidylcholine L-b,g-Dipalmitoyl-a-lecithin L-b,g-Dipalmitoyl-a-phosphatidylcholine L-b,g-Dipalmitoyl-alpha-lecithin L-b,g-Dipalmitoyl-alpha-phosphatidylcholine L-b,g-Dipalmitoylphosphatidylcholine Lecithin Lipid metabolic process Membrane integrity agent Membrane stability agent Nutraceutical PC 16:0/16:0 PC Aa C32:0 PC[16:0/16:0] PC[32:0] Palmitate de colfosceril Palmitic acid de colfosceril Phosphatidylcholine 16:0/16:0 Phosphatidylcholine[16:0/16:0] Phosphatidylcholine[32:0] Signal transduction Surface-active agent [R]-4-Hydroxy-N,N,N-trimethyl-10-oxo-7-[[1-oxohexadecyl]oxy]-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide hydroxide inner salt [R]-4-Hydroxy-N,N,N-trimethyl-10-oxo-7-[[1-oxohexadecyl]oxy]-3,5,9-trioxa-4-phosphapentacosan-1-aminium 4-oxide inner salt b,g-Dipalmitoyl L-a-phosphatidylcholine b,g-Dipalmitoyl L-alpha-phosphatidylcholine b,g-Dipalmitoyl-L-[a]-lecithin b,g-Dipalmitoyl-L-phosphatidylcholine gpcho 16:0/16:0 gpcho[16:0/16:0] gpcho[32:0] palmitato De colfoscerilo sn-3-Dipalmitoyllecithin
Chemical formula	C40H80NO8P
IUPAC name	(2-{[(2R)-2,3-bis(hexadecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium
CAS registry number	63-89-8
Monisotopic molecular weight	733.562155053
Chemical taxonomy
Super class	Lipids and lipid-like molecules
Class	Glycerophospholipids
Sub class	Glycerophosphocholines
Biological properties
Pahtways	Phosphatidylcholine Biosynthesis PC[16:0/16:0] Phosphatidylethanolamine Biosynthesis PE[16:0/16:0] Phospholipid Biosynthesis
Author-emphasized biomarker in the paper(s)	Muranishi et al. 2019

Lung cancer metabolomics studies that identify HMDB0000564 ('PC(16:0)', 'PC(16:0/16:0)', 'palmitoyl-palmitoyl-glycerophosphocholine')

Reference	Country	Specimen	Marker function	Participants (Case)						Participants (Control)
Reference	Country	Specimen	Marker function	Cancer type	Stage	Number	Gender (M,F)	Age mean (range) (M/F)	Smoking status	Type	Number	Gender (M,F)	Age mean (range) (M/F)	Smoking status
Chen et al. 2015	–	serum	–	lung cancer	–	30	–	61.58 ± 10.67	–	healthy	30	–	60.35 ± 12.48	–
Chen et al. 2015	–	serum	–	lung cancer	–	30	–	61.58 ± 10.67	–	before vs. after treatment (operation)	30	–	61.58 ± 10.67	–
Chen et al. 2018	–	serum	diagnosis	NSCLC	I, II	90	40, 50	58.1 ± 9.0	–	healthy	90	42, 48	53.0 ± 11.8	–
Callejon-Leblic et al. 2016	–	bronchoalveolar lavage fluid	diagnosis	lung cancer	–	24	16, 8	66 ± 11	–	noncancerous lung diseases	31	23, 8	56 ± 13	–
Muranishi et al. 2019	–	tissue	diagnosis	adenocarcinoma	I	25	–	46-82	–	tumor vs. adjacent normal tissue	25	–	46-82	–
Callejón-Leblic et al. 2019	–	blood	diagnosis	NSCLC, SCLC	II, III, IV	30	25, 5	67 ± 12	former, current, non-smoker	healthy	30	14, 16	56 ± 14	former, non-smoker
Moreno et al. 2018	–	tissue	therapy, diagnosis	squamous cell carcinoma	I, II, III	35	35, 0	68.71 ± 7.46	–	tumor vs. adjacent normal tissue	35	35, 0	68.71 ± 7.46	–
Moreno et al. 2018	–	tissue	therapy, diagnosis	squamous cell carcinoma	I, II, III	35	35, 0	68.71 ± 7.46	–	tumor vs. adjacent normal tissue	35	35, 0	68.71 ± 7.46	–

Reference	Chromatography	Ion source	Positive/Negative mode	Mass analyzer	Identification level
Chen et al. 2015	LC	ESI	positive	Q-TOF	–
Chen et al. 2015	LC	ESI	positive	Q-TOF	–
Chen et al. 2018	LC	ESI	positive/ negative	Q-TOF	–
Callejon-Leblic et al. 2016	DI	ESI	positive	Q-TOF	MS/MS
Muranishi et al. 2019	LC	ESI	positive	Q-TOF	MS/MS
Callejón-Leblic et al. 2019	DI	ESI	positive	Q-TOF	MS/MS
Moreno et al. 2018	LC, GC	ESI, EI	positive, negative	LC: linear ion‐trap, GC: single‐quadrupole	LC: MS/MS
Moreno et al. 2018	LC, GC	ESI, EI	positive, negative	LC: linear ion‐trap, GC: single‐quadrupole	LC: MS/MS

Reference	Data processing software	Database search
Chen et al. 2015	Mass Hunter Qualitative Analysis Software (Agilent Technologies)	METLIN
Chen et al. 2015	Mass Hunter Qualitative Analysis Software (Agilent Technologies)	METLIN
Chen et al. 2018	Analyst TF, XCMS	–
Callejon-Leblic et al. 2016	Markerview	HMDB, METLIN
Muranishi et al. 2019	Progenesis QI	LIPID MAPS, HMDB
Callejón-Leblic et al. 2019	–	HMDB, Metlin
Moreno et al. 2018	–	KEGG, HMDB
Moreno et al. 2018	–	KEGG, HMDB

Differential analysis
Classification analysis

Reference	Difference method	Mean concentration (case)	Mean concentration (control)	Fold change (case/control)	P-value	FDR	VIP
Chen et al. 2015	PCA, PLS-DA, independent t test	–	–	0.738157202841417	<0.001	–	1.309
Chen et al. 2015	PCA, PLS-DA, independent t test	–	–	1.22773568391506	<0.001	–	1.635
Chen et al. 2018	Student’s t-test	10094.11 ng/mL	8855.64 ng/mL	–	0.1	0.1	–
Callejon-Leblic et al. 2016	PLS-LDA, one-way ANOVA	–	–	0.6	0.047	–	1.69
Muranishi et al. 2019	Student's t test	–	–	–	0.0432	–	–
Callejón-Leblic et al. 2019	PCA, PLS-DA, one-way ANOVA	–	–	1.43	0.0003	–	1.25
Moreno et al. 2018	paired two‐sample t‐test, PLS-DA	–	–	0.533263842266742	0.000000000456294095081861	0.00000000234917863145371	–
Moreno et al. 2018	paired two‐sample t‐test, PLS-DA	–	–	0.477263899692257	0.0000000000000118629171366313	0.000000000000315553595834393	–

Reference	Classification method	Cutoff value	AUROC 95%CI	Sensitivity (%)	Specificity (%)	Accuracy (%)
Chen et al. 2015	–	–	–	–	–	–
Chen et al. 2015	–	–	–	–	–	–
Chen et al. 2018	ROC curve	–	–	–	–	–
Callejon-Leblic et al. 2016	ROC curve analysis	–	0.56	–	–	–
Muranishi et al. 2019	–	–	–	–	–	–
Callejón-Leblic et al. 2019	ROC curve	–	0.68	–	–	–
Moreno et al. 2018	–	–	–	–	–	–
Moreno et al. 2018	–	–	–	–	–	–